We are live on ! Find out more
NC

Nexthera Capital Portfolio holdings

AUM $120M
1-Year Est. Return 10.01%
This Fund
S&P 500
This Quarter Est. Return
-1.68%
1 Year Est. Return
+10.01%
3 Year Est. Return
+160.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$120M
AUM Growth
+$37.7M
Cap. Flow
+$41.9M
Cap. Flow %
34.93%
Top 10 Hldgs %
71.57%
Holding
35
New
11
Increased
11
Reduced
1
Closed
12

Top Buys

Rank Stock Value
1
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$12.6M
2
ASND icon
Ascendis Pharma A/S
ASND
+$7.21M
3
PCRX icon
Pacira BioSciences
PCRX
+$6.33M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$5.61M
5
CHRS icon
Coherus Oncology
CHRS
+$5.49M

Top Sells

Rank Stock Value
1
HRTX icon
Heron Therapeutics
HRTX
+$9.5M
2
BHC icon
Bausch Health
BHC
+$5.08M
3
STML
Stemline Therapeutics, Inc.
STML
+$4.18M
4
NVS icon
Novartis
NVS
+$3.83M
5
CBAY
Cymabay Therapeutics
CBAY
+$2.79M

Sector Composition

Rank Sector Weight
1 Healthcare 92.85%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EXEL icon
26
Exelixis
EXEL
$14B
– –
-90,356
Closed -$2.15M
HRTX icon
27
Heron Therapeutics
HRTX
$90.9M
– –
-388,623
Closed -$9.5M
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$4.81B
– –
-67,692
Closed -$1.22M
NVS icon
29
Novartis
NVS
$285B
– –
-50,587
Closed -$3.83M
SAGE
30
DELISTED
Sage Therapeutics
SAGE
– –
-6,200
Closed -$986K
DCPH
31
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
– –
-42,865
Closed -$995K
CBAY
32
DELISTED
Cymabay Therapeutics
CBAY
– –
-210,257
Closed -$2.79M
ACOR
33
DELISTED
Acorda Therapeutics
ACOR
– –
-1,290
Closed -$2.06M
CHMA
34
DELISTED
Chiasma, Inc. Common Stock
CHMA
– –
-203,948
Closed -$1.06M
STML
35
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-325,526
Closed -$4.18M
1
2

Similar funds

KAM
Kavi Asset Management New York $121M AUM 7.54% 1-Year Est. Return
VCP
Vernier Capital Partners New York $132M AUM 20.75% 1-Year Est. Return
PFC
Personal Financial Consultants Lafayette, California $133M AUM 5.06% 1-Year Est. Return
FCA
Florence Capital Advisors New York $105M AUM
TA
TMD & Associates Scottsdale, Arizona $146M AUM 1.29% 1-Year Est. Return
EBIM
Eagle Boston Investment Management Boston, Massachusetts $87.3M AUM 4.18% 1-Year Est. Return
BCM
BBT Capital Management Fort Worth, Texas $85.5M AUM 11.09% 1-Year Est. Return
ACP
ArcLight Capital Partners Boston, Massachusetts $83.2M AUM 32.11% 1-Year Est. Return

Nexthera Capital's Q2 2019 Portfolio in Review

As of Q2 2019, Nexthera Capital held 35 positions worth $120M, up 46% from $82.4M the previous quarter. Its ten largest holdings account for 72% of the portfolio.

Nexthera Capital deployed $41.9M of net new capital in Q2 2019, opening 11 new positions and adding to 11 existing holdings. Its largest new stake was Ascendis Pharma A/S: 60,266 shares worth $6.94M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 92% a quarter earlier.

On the sell side, the largest reduction was Allergan plc, an estimated $1.43M trimmed.

  • Nexthera Capital's largest Q2 2019 buy was Ascendis Pharma A/S: 60,266 shares worth $6.94M.
  • Nexthera Capital added most to Intercept Pharmaceuticals, Inc. in Q2 2019, an estimated $12.6M increase.
  • Nexthera Capital's biggest Q2 2019 reduction was Allergan plc, cutting an estimated $1.43M.
  • Nexthera Capital fully exited Heron Therapeutics in Q2 2019, selling an estimated $9.5M.
  • Nexthera Capital's ten largest holdings make up 72% of its $120M portfolio in Q2 2019.
  • Nexthera Capital opened 11 new positions and closed 12 in Q2 2019.
  • Nexthera Capital's portfolio value rose 46% quarter-over-quarter to $120M.

Based on Nexthera Capital's 13F filing for Q2 2019, filed 14 Aug 2019.